Clinical Trial Update: A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 study evaluating intrapulmonary penetration of nacubactam in healthy participants, with the trial now completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gram-negative Bacterial Infections

Drugs mentioned

• Nacubactam (nacubactam)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Gram-negative Bacterial Infections | Phase 1 | Status: COMPLETED